Table 2 PK/PD modelling of ex vivo data of enrofloxacin in healthy and Salmonella infected chickens after administration of 10 mg/kg b.w. of enrofloxacin.

From: The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium

Parameters

Unit

Healthy

Infected

Value

Dosage(mg/kg)

Value

Dosage(mg/kg)

Log E0

CFU/mL

−6.68

 

−7.01

 

Log Emax

CFU/mL

1.46

 

2.14

 

Slope (N)

—

9.40

 

4.96

 

AUC24/MIC EC50

h

465.15

 

684.21

 

AUC24/MIC for bacteriostatic action (E = 0)

h

395.67

2.22

538.64

3.03

AUC24/MIC for bactericidal action (E = −3)

h

474.76

2.67

719.33

4.04

AUC24/MIC for bacterial eradication (E = −4)

h

501.73

2.82

789.97

4.44

  1. E0: difference in bacterial count in control sample (without enrofloxacin) between 0 and 24 h; Emax: difference in bacterial count in sample incubated with enrofloxacin between 0 and 24 h, when the detection limit is reached; N: slope of the AUC24h/MIC-response curve; AUC24/MIC EC50: AUC24/MIC of drug producing 50% of the maximum antibacterial effect;
Back to article page